Logo image of AMRN

AMARIN CORP PLC -ADR (AMRN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AMRN - US0231114044 - ADR

14.14 USD
+0.44 (+3.21%)
Last: 12/26/2025, 8:00:00 PM
Fundamental Rating

3

Overall AMRN gets a fundamental rating of 3 out of 10. We evaluated AMRN against 530 industry peers in the Biotechnology industry. While AMRN seems to be doing ok healthwise, there are quite some concerns on its profitability. AMRN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AMRN has reported negative net income.
In the past year AMRN has reported a negative cash flow from operations.
In the past 5 years AMRN reported 4 times negative net income.
In the past 5 years AMRN reported 4 times negative operating cash flow.
AMRN Yearly Net Income VS EBIT VS OCF VS FCFAMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

AMRN has a better Return On Assets (-13.12%) than 81.70% of its industry peers.
AMRN has a Return On Equity of -18.87%. This is amongst the best in the industry. AMRN outperforms 83.77% of its industry peers.
Industry RankSector Rank
ROA -13.12%
ROE -18.87%
ROIC N/A
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
AMRN Yearly ROA, ROE, ROICAMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800

1.3 Margins

With a decent Gross Margin value of 54.96%, AMRN is doing good in the industry, outperforming 77.17% of the companies in the same industry.
In the last couple of years the Gross Margin of AMRN has declined.
AMRN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
AMRN Yearly Profit, Operating, Gross MarginsAMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

6

2. Health

2.1 Basic Checks

AMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AMRN has more shares outstanding
AMRN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for AMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AMRN Yearly Shares OutstandingAMRN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
AMRN Yearly Total Debt VS Total AssetsAMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -1.73, we must say that AMRN is in the distress zone and has some risk of bankruptcy.
AMRN has a Altman-Z score (-1.73) which is comparable to the rest of the industry.
AMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.73
ROIC/WACCN/A
WACC7.54%
AMRN Yearly LT Debt VS Equity VS FCFAMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

AMRN has a Current Ratio of 3.45. This indicates that AMRN is financially healthy and has no problem in meeting its short term obligations.
AMRN has a Current ratio of 3.45. This is comparable to the rest of the industry: AMRN outperforms 41.51% of its industry peers.
A Quick Ratio of 2.43 indicates that AMRN has no problem at all paying its short term obligations.
The Quick ratio of AMRN (2.43) is worse than 69.62% of its industry peers.
Industry RankSector Rank
Current Ratio 3.45
Quick Ratio 2.43
AMRN Yearly Current Assets VS Current LiabilitesAMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

AMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.56%, which is quite impressive.
The Revenue has decreased by -5.93% in the past year.
AMRN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.86% yearly.
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.67%
Revenue 1Y (TTM)-5.93%
Revenue growth 3Y-26.81%
Revenue growth 5Y-11.86%
Sales Q2Q%17.43%

3.2 Future

AMRN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.76% yearly.
AMRN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.83% yearly.
EPS Next Y56.42%
EPS Next 2Y44.5%
EPS Next 3Y24.81%
EPS Next 5Y17.76%
Revenue Next Year10.03%
Revenue Next 2Y-0.3%
Revenue Next 3Y-0.52%
Revenue Next 5Y26.83%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AMRN Yearly Revenue VS EstimatesAMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
AMRN Yearly EPS VS EstimatesAMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8 -10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

AMRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 72.96, the valuation of AMRN can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AMRN indicates a rather cheap valuation: AMRN is cheaper than 89.43% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of AMRN to the average of the S&P500 Index (23.46), we can say AMRN is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 72.96
AMRN Price Earnings VS Forward Price EarningsAMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMRN Per share dataAMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

AMRN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as AMRN's earnings are expected to grow with 24.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.5%
EPS Next 3Y24.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMRN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

AMARIN CORP PLC -ADR

NASDAQ:AMRN (12/26/2025, 8:00:00 PM)

14.14

+0.44 (+3.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2025-10-29/bmo
Earnings (Next)03-10 2026-03-10/amc
Inst Owners20.09%
Inst Owner Change-4.09%
Ins Owners0.81%
Ins Owner Change0%
Market Cap294.01M
Revenue(TTM)226.73M
Net Income(TTM)-86.57M
Analysts42.86
Price Target12.24 (-13.44%)
Short Float %40.43%
Short Ratio3.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)290.01%
Min EPS beat(2)113.76%
Max EPS beat(2)466.25%
EPS beat(4)3
Avg EPS beat(4)148.54%
Min EPS beat(4)-30.72%
Max EPS beat(4)466.25%
EPS beat(8)6
Avg EPS beat(8)97.31%
EPS beat(12)7
Avg EPS beat(12)68.9%
EPS beat(16)9
Avg EPS beat(16)50.01%
Revenue beat(2)2
Avg Revenue beat(2)22.82%
Min Revenue beat(2)12.99%
Max Revenue beat(2)32.65%
Revenue beat(4)3
Avg Revenue beat(4)24.22%
Min Revenue beat(4)-18.83%
Max Revenue beat(4)70.07%
Revenue beat(8)5
Avg Revenue beat(8)16.46%
Revenue beat(12)9
Avg Revenue beat(12)12.72%
Revenue beat(16)10
Avg Revenue beat(16)8.28%
PT rev (1m)5.88%
PT rev (3m)9.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)114.29%
EPS NY rev (1m)56.28%
EPS NY rev (3m)56.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)32.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)15.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 72.96
P/S 1.3
P/FCF N/A
P/OCF N/A
P/B 0.64
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)-0.62
EYN/A
EPS(NY)0.19
Fwd EY1.37%
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS10.9
BVpS22.07
TBVpS21.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.12%
ROE -18.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.96%
FCFM N/A
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.45
Quick Ratio 2.43
Altman-Z -1.73
F-Score4
WACC7.54%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.67%
EPS Next Y56.42%
EPS Next 2Y44.5%
EPS Next 3Y24.81%
EPS Next 5Y17.76%
Revenue 1Y (TTM)-5.93%
Revenue growth 3Y-26.81%
Revenue growth 5Y-11.86%
Sales Q2Q%17.43%
Revenue Next Year10.03%
Revenue Next 2Y-0.3%
Revenue Next 3Y-0.52%
Revenue Next 5Y26.83%
EBIT growth 1Y34.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.11%
EBIT Next 3Y20.89%
EBIT Next 5YN/A
FCF growth 1Y-354.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-337.33%
OCF growth 3YN/A
OCF growth 5YN/A

AMARIN CORP PLC -ADR / AMRN FAQ

What is the fundamental rating for AMRN stock?

ChartMill assigns a fundamental rating of 3 / 10 to AMRN.


What is the valuation status of AMARIN CORP PLC -ADR (AMRN) stock?

ChartMill assigns a valuation rating of 2 / 10 to AMARIN CORP PLC -ADR (AMRN). This can be considered as Overvalued.


Can you provide the profitability details for AMARIN CORP PLC -ADR?

AMARIN CORP PLC -ADR (AMRN) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for AMRN stock?

The Earnings per Share (EPS) of AMARIN CORP PLC -ADR (AMRN) is expected to grow by 56.42% in the next year.